China Issues, Health Transformation & AI
The Deep Restructuring of Healthineers Bases on a Strong Core Business
Siemens Healthineers reported mixed Q2 results: Imaging and Precision Therapy are performing strongly, the Diagnostics division is struggling with structural issues. However, the global medical player faces more than just an operational challenge; it is in a state of upheaval ahead of the spin-off.
»Although the environment remains challenging, our synergistic core of Imaging and Precision Therapy continues to be on track with strong momentum,« said CEO Bernd Montag when presenting the quarterly results on May 7, 2026. That sounds like routine optimism—but it isn’t. For while Montag speaks, a historic corporate restructuring is underway in the background: separation from Siemens AG, carve-out of the Diagnostics division, a new leadership team, a new AI strategy. All at once.
Imaging and Varian as Key Drivers
In the second quarter of fiscal year 2026 (ending March 31), the Imaging segment grew by 6.1 percent on a comparable basis to just under 3.0 billion euros—a remarkable figure given the strong prior-year base of 8 percent. Growth was driven by magnetic resonance imaging, molecular imaging, and photon-counting CT, which continues to grow. The margin declined slightly to 22.4 percent; customs and currency effects account for the decline, while the operating margin remained at the prior-year level.
In cancer treatment, Varian is now delivering reliably: The Precision Therapy segment grew by 4.7 percent on a comparable basis to around 1.7 billion euros, while Varian itself grew by 7.5 percent—the Varian margin rose to 14.6 percent from 13.2 percent in the previous year. The former integration burden of the 2020 billion-euro acquisition is increasingly becoming a pillar of growth. Total revenue was just under 5.7 billion euros, up 3.1 percent on a comparable basis; adjusted earnings per share were 0.53 euros—nearly at the previous year’s level; adjusted for FX and tariff effects, this would represent approximately 16 percent growth.
The diagnostics issues are becoming more entrenched
In contrast, the downward spiral in the Diagnostics segment continues. Revenue fell by 6.5 percent on a comparable basis to just under one billion euros, while the adjusted EBIT margin dropped from 6.3 to 0.9 percent. The main driver is China: government-led anti-corruption campaigns and a centralized procurement system have structurally transformed the market—this is no longer a short-term slump but is developing into a long-term burden.
Montag had already publicly admitted back in April that Healthineers »may no longer be the best owner« of this unit—a remarkable statement that has since established the spin-off scenario as a serious option.
Strategic Realignment: Carve-outs and Spin-offs
Alongside its quarterly results, Healthineers is outlining its future structure with unusual specificity. The parent company, Siemens AG, plans to put the complete spin-off of Siemens Healthineers to a vote at the next annual general meetings—expected in early 2027; the banking consortium for the refinancing is already in place. The spin-off and the Diagnostics carve-out are two sides of the same coin: the company is scaling back to its core business.
According to the company, an independent setup for Diagnostics is intended to keep »a full spectrum of options« open—from a sale to an initial public offering. Montag had already set the tone back in February: »2026 will be a year of special significance for our company. Following a potential deconsolidation, we want to be an attractive investment for more owners than ever before.«
Generational Shift in the Leadership team
This strategic realignment is accompanied by a targeted restructuring of the workforce, which Montag himself describes as a »comprehensive generational shift.« The most notable sign of this is the appointment of Martin Stumpe as the new Chief Technology Officer—who will report directly to Montag starting June 1, 2026.
Martin Stumpe will assume the role of Chief Technology Officer at Siemens Healthineers effective June 1, 2026. The AI expert joins from Danaher and is tasked with embedding the company’s healthcare AI strategy at the executive level.
Stumpe founded the cancer pathology project at Google Brain, advanced precision medicine at Tempus AI, and most recently served as Chief Technology & AI Officer at Danaher. For Montag, he is »a key factor in strengthening our leadership in healthcare AI—as a central link to our strategic strengths in patient twinning and precision therapy.«
Also new: Andreas Schneck is taking over as head of Diagnostic Imaging. As the former head of MR and General Manager of the MR plant in Shenzhen, he played a key role in shaping Healthineers’ global growth and localization strategy in China—an experience that is not without symbolic significance in the company’s current debate regarding China.
Philipp Fischer, a trained physician specializing in cardiology and angiography, is taking over Advanced Therapies; he was previously responsible for the CT business and played a key role in establishing the PCCT line. Finally, Sonja Wehsely will become the new head of the EMEA region: The former Vienna City Councilor for Health and long-time Siemens Healthineers manager combines extensive experience in public health policy with operational responsibility in global medtech.
The four names complement each other: Stumpe represents the AI future of the core business, Schneck and Fischer represent technological depth in the growth segments, and Wehsely represents the bridge between health policy and the market.
States' Health Insurance Reform as a New Burden
While China and tariffs have long been known sources of pressure, the German healthcare reform adds a new risk factor. The Federal Cabinet has launched an austerity package aimed at saving around 20 billion euros in the statutory health insurance system by 2027—more than 40 percent of which will directly affect the hospital sector. This hits Siemens Healthineers in a sensitive spot in its home market: hospitals are the main buyers of imaging systems and laboratory diagnostics.
According to industry data, two-thirds of German hospitals are already operating at a loss, and the willingness to invest in expensive equipment requires financial leeway. While the Hospital Transformation Fund, with a volume of up to 50 billion euros over ten years, is intended to provide a boost for medical technology investments, the short-term impact of the austerity package is likely to dampen the investment cycle at German hospitals for the time being. This factor does not yet appear as a figure in the quarterly report, but as a structural market risk, it is difficult for Healthineers to ignore in Germany.
Forecast Lowered – with Reservations
Healthineers has revised its updated full-year outlook downward: comparable revenue growth is now expected to be between 4.5% and 5.0% (previously 5% to 6%), and adjusted EPS between €2.20 and €2.30—the upper limit of €2.40 has been removed. A new item has been added: increased supply chain inflation, which is expected to impact operating profit in the second half of the year by a mid- to high-double-digit million euro amount. The forecast explicitly does not include a buffer for a potential U.S. tariff refund—if this were to occur, it would be a positive wild card for the second half of the year.
Montag’s »synergistic core« is more than just a buzzword—it is a strategic dividing line. What belongs to it will be strengthened and enhanced with AI capabilities. What does not belong to it will have its own future. For Diagnostics, this means: The question is no longer whether, but exactly what the separation will look like.
